Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2416 to 2430 of 7685 results

  1. Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

    In development [GID-TA10990] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  2. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]

    In development [GID-TA11197] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Laparoscopic insertion of a non-active implant for gastro-oesophageal reflux disease

    In development [GID-IPG10345] Expected publication date: 17 April 2025

    Interventional procedures guidance
    In development

  5. Gambling-related harms: identification, assessment and management

    In development [GID-NG10210] Expected publication date: TBC

    NICE guideline
    In development

  6. Drug-eluting coronary stents for treating coronary artery disease: late-stage assessment

    In development [GID-HTE10039] Expected publication date: 12 May 2025

    Health technology evaluations
    In development

  7. Pulsed field ablation for atrial fibrillation

    In development [GID-IPG10267] Expected publication date: 09 July 2025

    Interventional procedures guidance
    In development

  8. Resminostat for maintenance treatment of advanced mycosis fungoides or Sézary syndrome ID6478

    Awaiting development [GID-TA11606] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Dupilumab for treating bullous pemphigoid [ID6479]

    Awaiting development [GID-TA11615] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

    In development [GID-TA11439] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]

    In development [GID-TA11398] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tolebrutinib for treating relapsing multiple sclerosis ID6351

    Awaiting development [GID-TA11333] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409

    In development [GID-TA11508] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Iclepertin for treating cognitive impairment associated with schizophrenia ID6483

    Awaiting development [GID-TA11647] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Robot-assisted surgery for soft-tissue procedures: early value assessment

    In development [GID-HTE10040] Expected publication date: 31 March 2025

    Health technology evaluations
    In development